BiotechTube
Prediction BioSciences

Prediction BioSciences

Paris, France· Est.
predict.net
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

Prediction BioSciences is a French biotech founded in 2016, targeting the high-unmet-need areas of stroke and neurodegenerative disorders. The company leverages a multi-pronged technological strategy involving diagnostics and novel therapeutic delivery systems like exosomes. While still in the clinical development stage, it has assembled a team with strong academic and industry experience and is supported by strategic partnerships and public funding.

StrokeNeurodegenerative Diseases

Technology Platform

Integrated platform combining plasma-based biomarker diagnostics, engineered exosomes for targeted drug delivery to the brain, and a focus on cell-type specific targets. Includes the GeneRx™ computational modeling platform.

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

The large and growing unmet need in stroke and neurodegenerative diseases presents a major market opportunity.
The company's dual diagnostic/therapeutic approach could de-risk development and create multiple revenue streams.
Its exosome delivery platform has broad potential applicability across neurology and other therapeutic areas.

Risk Factors

High scientific risk associated with the complexity of neurological diseases and the nascent exosome delivery technology.
Significant financial risk as a pre-revenue company dependent on fundraising.
Intense competition from larger, better-funded entities in the same therapeutic space.

Competitive Landscape

Prediction BioSciences operates in highly competitive fields with numerous large pharma (e.g., Biogen, Roche) and biotech companies pursuing diagnostics and therapeutics for Alzheimer's, Parkinson's, and stroke. Its differentiation lies in its integrated platform combining diagnostics with a novel exosome-based delivery system, but it must compete for funding, talent, and clinical validation.

More companies in Neuroscience & CNS →More companies in France →